What is the appropriate Risperdal Consta (risperidone long‑acting injectable) dose conversion for a patient taking 2 mg oral risperidone nightly?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Uzedy LAI Conversion from 2mg Oral Risperidone

I cannot provide a conversion to Uzedy LAI because the evidence provided does not contain any information about Uzedy (risperidone extended-release injectable suspension), which is a distinct long-acting injectable formulation from Risperdal Consta.

What the Evidence Shows

The provided evidence only addresses Risperdal Consta (risperidone microspheres), not Uzedy. These are different formulations with different pharmacokinetic profiles and conversion strategies:

For Risperdal Consta Conversion (Not Uzedy):

Based on FDA labeling and research evidence, for a patient taking 2mg oral risperidone nightly, the Risperdal Consta conversion would be 25mg IM every 2 weeks 1.

  • Oral supplementation required: Continue oral risperidone (or another antipsychotic) for 3 weeks after the first Risperdal Consta injection, then discontinue 1
  • Research supports this conversion, with one study suggesting patients on oral risperidone ≤3mg/day should receive 25mg Risperdal Consta 2
  • Another study found patients on ≤4mg oral risperidone were appropriately converted to 25mg Risperdal Consta 3

Critical Distinction

Uzedy is NOT Risperdal Consta. Uzedy has:

  • Different release kinetics
  • Different dosing intervals (monthly or every 2 months)
  • Different conversion protocols
  • Different supplementation requirements

To obtain accurate Uzedy conversion information, you must consult:

  • Uzedy FDA prescribing information specifically
  • Uzedy-specific conversion guidelines
  • Product manufacturer resources for Uzedy

The conversion strategies for Risperdal Consta cannot be extrapolated to Uzedy due to fundamentally different formulation characteristics.

References

Related Questions

For a patient currently stable on oral risperidone 4 mg daily who wishes to switch to the long‑acting injectable formulation (Risperdal Consta), what dose should be used?
What dose of Uzedy (long‑acting injectable risperidone) is appropriate for a patient taking 4 mg oral risperidone?
How can a patient stable on oral risperidone 5 mg daily be switched to a long‑acting injectable formulation (e.g., Risperdal Consta or Perseris)?
What is the appropriate method to switch a patient from risperidone 250 mg subcutaneous depot administered every two months to an equivalent oral risperidone regimen?
Is a starting schedule of risperidone 1 mg tablets consisting of a half tablet (0.5 mg) each morning for seven days followed by a full tablet (1 mg) each night an appropriate regimen?
When does a renal cyst require biopsy?
What are the adverse effects of darolutamide (600 mg taken orally twice daily with food)?
In an 82‑year‑old male with a newly diagnosed low‑grade non‑invasive bladder tumor who now has bladder pain after trauma, should an antibiotic be prescribed and, if so, which regimen is appropriate?
In a patient with ulcerative colitis receiving a tumor necrosis factor (TNF) inhibitor, which of the following organisms is NOT a potential cause of infection: Listeria monocytogenes, Mycobacterium tuberculosis, Haemophilus influenzae, Cytomegalovirus, or none of the above?
What is the recommended starting dose of fenofibrate for an adult with a triglyceride level of 569 mg/dL?
Can you assess this Comprehensive Metabolic Panel (CMP) with sodium 131 mmol/L (low), potassium 3.1 mmol/L (low), chloride 90 mmol/L (low), carbon dioxide 34 mmol/L (high), albumin 2.0 g/dL (low), globulin 4.6 g/dL (high), albumin‑globulin ratio 0.4, BUN/creatinine ratio 23.3, and other values within normal limits?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.